Todays Report: Today: FY2018 EPS Estimates for TG Therapeutics Inc. (TGTX) Cut by FBR & Co

Today: FY2018 EPS Estimates for TG Therapeutics Inc. (TGTX) Cut by FBR & Co

TG Therapeutics Inc. (NASDAQ:TGTX) – Stock analysts at FBR & Co lowered their FY2018 EPS estimates for shares of TG Therapeutics in a report issued on Wednesday. FBR & Co analyst E. White now forecasts that the firm will post earnings per share of ($1.63) for the year, down from their prior estimate of ($1.60). FBR & Co currently has a “Buy” rating on the stock.

TGTX has been the topic of several other reports. Roth Capital reissued a “buy” rating and issued a $33.00 price objective on shares of TG Therapeutics in a report on Wednesday, August 10th. S&P Equity Research dropped their price objective on TG Therapeutics from $7.15 to $6.40 in a report on Wednesday, August 24th. HC Wainwright reaffirmed a “buy” rating and issued a $18.00 price target (down from $22.00) on shares of TG Therapeutics in a research note on Saturday, October 15th. Zacks Investment Research raised TG Therapeutics from a “hold” rating to a “buy” rating and set a $6.50 price target on the stock in a research note on Thursday, October 20th. Finally, Brean Capital reaffirmed a “buy” rating and issued a $28.00 price target on shares of TG Therapeutics in a research note on Thursday, October 6th. One investment analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. TG Therapeutics has an average rating of “Buy” and a consensus target price of $20.86.

TG Therapeutics (NASDAQ:TGTX) opened at 5.7851 on Monday. The company’s market cap is $316.62 million. The firm has a 50-day moving average price of $6.13 and a 200 day moving average price of $6.63. TG Therapeutics has a 12 month low of $4.90 and a 12 month high of $14.87.

TG Therapeutics (NASDAQ:TGTX) last announced its quarterly earnings data on Monday, November 7th. The biopharmaceutical company reported ($0.50) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.31) by $0.19. TG Therapeutics had a negative net margin of 47,494.08% and a negative return on equity of 83.18%.

Institutional investors have recently made changes to their positions in the company. Teachers Advisors Inc. increased its position in shares of TG Therapeutics by 5.5% in the second quarter. Teachers Advisors Inc. now owns 56,545 shares of the biopharmaceutical company’s stock worth $343,000 after buying an additional 2,961 shares during the last quarter. Alliancebernstein L.P. increased its position in shares of TG Therapeutics by 33.9% in the second quarter. Alliancebernstein L.P. now owns 61,240 shares of the biopharmaceutical company’s stock worth $371,000 after buying an additional 15,500 shares during the last quarter. Trexquant Investment LP bought a new position in shares of TG Therapeutics during the second quarter worth approximately $264,000. BlackRock Investment Management LLC increased its position in shares of TG Therapeutics by 5.7% in the second quarter. BlackRock Investment Management LLC now owns 149,087 shares of the biopharmaceutical company’s stock worth $903,000 after buying an additional 8,102 shares during the last quarter. Finally, BlackRock Advisors LLC increased its position in shares of TG Therapeutics by 14.5% in the second quarter. BlackRock Advisors LLC now owns 18,131 shares of the biopharmaceutical company’s stock worth $110,000 after buying an additional 2,296 shares during the last quarter. Hedge funds and other institutional investors own 49.50% of the company’s stock.

About TG Therapeutics

Related posts

Leave a Comment